During the current project period, CCSG Developmental Funds were efficiently and productively used to fund innovative Pilot cancer research projects and provide critical support to developing Shared Resources. In the current application, YCC proposes focusing the allotted Developmental Funds entirely on the Pilot Project Program, a highly successful intramural grants program to stimulate innovative, early stage cancer research. In addition to the Pilot Projects, in which individual investigators receive funding for research projects, YCC members can also compete for funding of larger multi-Investigator projects for collaborative, transdisciplinary work. In a new program, YCC members collaborating with cancer investigators from University College London are also eligible for collaborative multi-institutional project awards, which create closer research interactions between the two Institutions. In recognition of the strategic imperative of strengthening translational research, Translational Targeted Areas of Research Excellence (T-TARE) Awards were initiated in 2011 to support translational research in cancer, requiring a collaborative effort among 3 or more YCC members. These research projects match clinical and basic scientists in ongoing productive collaborations and are designed to evolve into successful translational applications and new clinical trials. Pilot awards are intended to facilitate and expedite the maturation of individual as well as collaborative projects into external peer-reviewed funding, anchored in the YCC.

Public Health Relevance

Developmental Funds from the CCSG have been used effectively by YCC investigators to expand cancer research in alignment with center-wide and programmatic priorities. The Pilot Project Program supports new research projects that are innovative, collaborative, transdisciplinary, and translational in approach and is likely to result in additional external peer-reviewed funding.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Yale University
New Haven
United States
Zip Code
Wimberly, Hallie; Brown, Jason R; Schalper, Kurt et al. (2015) PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunol Res 3:326-32
Ma, Xiaomei; Wang, Rong; Long, Jessica B et al. (2014) The cost implications of prostate cancer screening in the Medicare population. Cancer 120:96-102
Herbst, Roy S; Soria, Jean-Charles; Kowanetz, Marcin et al. (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563-7
Durazzo, Tyler S; Tigelaar, Robert E; Filler, Renata et al. (2014) Induction of monocyte-to-dendritic cell maturation by extracorporeal photochemotherapy: initiation via direct platelet signaling. Transfus Apher Sci 50:370-8
Black, Jonathan D; English, Diana P; Roque, Dana M et al. (2014) Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer. Womens Health (Lond Engl) 10:45-57
Smith, Matthew R; Halabi, Susan; Ryan, Charles J et al. (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143-50
Cao, Jian; Liu, Zongzhi; Cheung, William K C et al. (2014) Histone demethylase RBP2 is critical for breast cancer progression and metastasis. Cell Rep 6:868-77
Gonzalez, A L; Berger, C L; Remington, J et al. (2014) Integrin-driven monocyte to dendritic cell conversion in modified extracorporeal photochemotherapy. Clin Exp Immunol 175:449-57
O'Malley, Stephanie S; Wu, Ran; Mayne, Susan T et al. (2014) Smoking cessation is followed by increases in serum bilirubin, an endogenous antioxidant associated with lower risk of lung cancer and cardiovascular disease. Nicotine Tob Res 16:1145-9
Chen, Lieping (2014) From the guest editor: Tumor site immune modulation therapy. Cancer J 20:254-5

Showing the most recent 10 out of 72 publications